-
公开(公告)号：BR9913888A
公开(公告)日：2002-01-08
申请号：BR9913888
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B , JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：AU752474B2
公开(公告)日：2002-09-19
申请号：AU6047599
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B , RAFFERTY PAUL , TOMETZKI GERALD B , JOHNSTON DAVID N , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：ZA200102201B
公开(公告)日：2002-03-15
申请号：ZA200102201
申请日：2001-03-16
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE , GAVIN MAZDIYASNI HORMOZ HIRST , DENG BOJUAN , JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , C07D , A61K
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
Patent Agency Ranking
公开(公告)号：SK3852001A3
公开(公告)日：2003-03-04
申请号：SK3852001
申请日：1999-09-17
Applicant: BASF AG
Inventor： JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER , CALDERWOOD DAVID , ARNOLD LEE , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：BG105355A
公开(公告)日：2001-11-30
申请号：BG10535501
申请日：2001-03-16
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B , JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/505 , C07D487/04
Abstract: Chemical compounds having the structural formula and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders. 45 claims
-
公开(公告)号：TR200101395T2
公开(公告)日：2001-11-21
申请号：TR200101395
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B , JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：CA2344262A1
公开(公告)日：2000-03-30
申请号：CA2344262
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , DENG BOJUAN B , MAZDIYASNI HORMOZ , HIRST GAVIN , RAFFERTY PAUL , JOHNSTON DAVID N , TOMETZKI GERALD B , MUNSCHAUER RAINER , TWIGGER HELEN L
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
公开(公告)号：PL347138A1
公开(公告)日：2002-03-25
申请号：PL34713899
申请日：1999-09-17
Applicant: BASF AG
Inventor： CALDERWOOD DAVID , ARNOLD LEE D , MAZDIYASNI HORMOZ , HIRST GAVIN , DENG BOJUAN B , JOHNSTON DAVID N , RAFFERTY PAUL , TOMETZKI GERALD B , TWIGGER HELEN L , MUNSCHAUER RAINER
IPC: A61K31/519 , A61P1/04 , A61P3/10 , A61P9/00 , A61P11/00 , A61P15/00 , A61P17/02 , A61P19/02 , A61P27/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.018 seconds)
